Defining the Role of Sirolimus in the Management of Graft-versus-Host Disease: From Prophylaxis to Treatment

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 1, 2013, Pages 12-21

  Abouelnasr, Ahmed ^a,b   Roy, Jean ^a   Cohen, Sandra ^a   Kiss, Thomas ^a   Lachance, Silvy ^a  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^b NATIONAL CANCER INSTITUTE   (Egypt)

Author keywords

Sirolimus role in GHVD management

Indexed keywords

METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ANTINEOPLASTIC ACTIVITY; CYTOMEGALOVIRUS; DISEASE FREE SURVIVAL; DRUG MECHANISM; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOADING DRUG DOSE; MORTALITY; OVERALL SURVIVAL; RECURRENCE FREE SURVIVAL; RELAPSE; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TREATMENT FAILURE; VIRUS REACTIVATION;

FEMALE; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; RECURRENCE; SIROLIMUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84871923117     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.06.020     Document Type: Review

References (68)

1. Johnson R.W. Sirolimus (Rapamune) in renal transplantation. Curr Opin Nephrol Hypertens 2002, 11:603-607.
2. Trotter J.F. Sirolimus in liver transplantation. Transplant Proc 2003, 35(3 suppl):193S-200S.
3. Sehgal S.N. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998, 31:335-340.
4. Sehgal S.N. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 2003, 35(3 Suppl):7S-14S.
5. Ciancio G., Burke G.W., Gaynor J.J., et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation 2004, 77:252-258.
6. Ciancio G., Burke G.W., Gaynor J.J., et al. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Transplantation 2004, 77:244-251.
7. Koenen H.J., Michielsen E.C., Verstappen J., Fasse E., Joosten I. Superior T-cell suppression by rapamycin and FK506 over rapamycin and cyclosporine A because of abrogated cytotoxic T-lymphocyte induction, impaired memory responses, and persistent apoptosis. Transplantation 2003, 75:1581-1590.
8. Slavik J.M., Lim D.G., Burakoff S.J., Hafler D.A. Uncoupling p70(s6) kinase activation and proliferation: rapamycin-resistant proliferation of human CD8(+) T lymphocytes. J Immunol 2001, 166:3201-3209.
9. Hackstein H., Taner T., Logar A.J., Thomson A.W. Rapamycin inhibits macropinocytosis and mannose receptor-mediated endocytosis by bone marrow-derived dendritic cells. Blood 2002, 100:1084-1087.
10. Monti P., Mercalli A., Leone B.E., Valerio D.C., Allavena P., Piemonti L. Rapamycin impairs antigen uptake of human dendritic cells. Transplantation 2003, 75:137-145.
11. Hackstein H., Taner T., Zahorchak A.F., et al. Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 2003, 101:4457-4463.
12. Chiang P.H., Wang L., Liang Y., et al. Inhibition of IL-12 signaling Stat4/IFN-gamma pathway by rapamycin is associated with impaired dendritic [correction of dendritc] cell function. Transplant Proc 2002, 34:1394-1395.
13. Woltman A.M., de Fijter J.W., Kamerling S.W., et al. Rapamycin induces apoptosis in monocyte- and CD34-derived dendritic cells but not in monocytes and macrophages. Blood 2001, 98:174-180.
14. Woltman A.M., van der Kooij S.W., Coffer P.J., Offringa R., Daha M.R., van Kooten C. Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression. Blood 2003, 101:1439-1445.
15. Battaglia M., Stabilini A., Roncarolo M.G. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005, 105:4743-4748.
16. Ruggenenti P., Perico N., Gotti E., et al. Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury. Transplantation 2007, 84:956-964.
17. Salas-Prato M., Assalian A., Mehdi A.Z., Duperré J., Thompson P., Brazeau P. Inhibition by rapamycin of PDGF- and bFGF-induced human tenon fibroblast proliferation in vitro. J Glaucoma 1996, 5:54-59.
18. Zhu J., Wu J., Frizell E., et al. Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis. Gastroenterology 1999, 117:1198-1204.
19. Jain S., Bicknell G.R., Whiting P.H., Nicholson M.L. Rapamycin reduces expression of fibrosis-associated genes in an experimental model of renal ischaemia reperfusion injury. Transplant Proc 2001, 33:556-558.
20. Shegogue D., Trojanowska M. Mammalian target of rapamycin positively regulates collagen type I production via a phosphatidylinositol 3-kinase-independent pathway. J Biol Chem 2004, 279:23166-23175.
21. Platzbecker U., Haase M., Herbst R., et al. Activity of sirolimus in patients with myelodysplastic syndrome-results of a pilot study. Br J Haematol 2005, 128:625-630.
22. Xu Q., Simpson S.E., Scialla T.J., Bagg A., Carroll M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 2003, 102:972-980.
23. Gingras A.C., Raught B., Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001, 15:807-826.
24. Récher C., Beyne-Rauzy O., Demur C., et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005, 105:2527-2534.
25. Chan S.M., Weng A.P., Tibshirani R., Aster J.C., Utz P.J. Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Blood 2007, 110:278-286.
26. Marty F.M., Bryar J., Browne S.K., et al. Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood 2007, 110:490-500.
27. Krams S.M., Martinez O.M. Epstein-Barr virus, rapamycin, and host immune responses. Curr Opin Organ Transplant 2008, 13:563-568.
28. Majewski M., Korecka M., Kossev P., et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci U S A 2000, 97:4285-4290.
29. Cen O., Longnecker R. Rapamycin reverses splenomegaly and inhibits tumor development in a transgenic model of Epstein-Barr virus-related Burkitt's lymphoma. Mol Cancer Ther 2011, 10:679-686.
30. Garcia V.D., Bonamigo Filho J.L., Neumann J., et al. Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment. Transpl Int 2003, 16:202-206.
31. Matthews K., Gossett J., Kappelle P.V., Jellen G., Pahl E. Indications, tolerance and complications of a sirolimus and calcineurin inhibitor immunosuppression regimen: intermediate experience in pediatric heart transplantation recipients. Pediatr Transplant 2010, 14:402-408.
32. Gibelli N.E., Tannuri U., Pinho-Apezzato M.L., et al. Sirolimus in pediatric liver transplantation: a single-center experience. Transplant Proc 2009, 41:901-903.
33. Hong J.C., Kahan B.D. Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management. Transplantation 2000, 69:2085-2090.
34. Tenderich G., Fuchs U., Zittermann A., Muckelbauer R., Berthold H.K., Koerfer R. Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients. Clin Transplant 2007, 21:536-543.
35. Kahan B.D., Podbielski J., Napoli K.L., Katz S.M., Meier-Kriesche H.U., Van Buren C.T. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 1998, 66:1040-1046.
36. Murgia M.G., Jordan S., Kahan B.D. The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int 1996, 49:209-216.
37. Kuppahally S., Al-Khaldi A., Weisshaar D., et al. Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients. Am J Transplant 2006, 6(5 Pt 1):986-992.
38. Cao W., Mohacsi P., Shorthouse R., Pratt R., Morris R.E. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. Transplantation 1995, 59:390-395.
39. Champion L., Stern M., Israël-Biet D., et al. Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. Ann Intern Med 2006, 144:505-509.
40. Mahé E., Morelon E., Lechaton S., et al. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation 2005, 79:476-482.
41. Smith M.P., Newstead C.G., Ahmad N., et al. Poor tolerance of sirolimus in a steroid avoidance regimen for renal transplantation. Transplantation 2008, 85:636-639.
42. Cutler C., Henry N.L., Magee C., et al. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005, 11:551-557.
43. Robson M., Côte I., Abbs I., Koffman G., Goldsmith D. Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage?. Am J Transplant 2003, 3:324-327.
44. Saikali J.A., Truong L.D., Suki W.N. Sirolimus may promote thrombotic microangiopathy. Am J Transplant 2003, 3:229-230.
45. Barone G.W., Gurley B.J., Abul-Ezz S.R., Gökden N. Sirolimus-induced thrombotic microangiopathy in a renal transplant recipient. Am J Kidney Dis 2003, 42:202-206.
46. Jedlickova Z., Burlakova I., Bug G., Baurmann H., Schwerdtfeger R., Schleuning M. Therapy of sclerodermatous chronic graft-versus-host disease with mammalian target of rapamycin inhibitors. Biol Blood Marrow Transplant 2011, 17:657-663.
47. Groth C.G., Brattström C., Claesson K., Bäckman L. New trails in transplantation: how to exploit the potential of sirolimus in clinical transplantation. Transplant Proc 1998, 30:4064-4065.
48. Kahan B.D. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000, 356:194-202.
49. MacDonald A.S. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001, 71:271-280. RAPAMUNE Global Study Group.
50. Podder H., Stepkowski S.M., Napoli K.L., et al. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol 2001, 12:1059-1071.
51. Ho V.T., Aldridge J., Kim H.T., et al. Comparison of tacrolimus and sirolimus (Tac/Sir) versus tacrolimus, sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2009, 15:844-850.
52. Rodriguez R., Nakamura R., Palmer J.M., et al. A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. Blood 2010, 115:1098-1105.
53. Cutler C., Li S., Ho V.T., et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 2007, 109:3108-3114.
54. Rosenbeck L.L., Kiel P.J., Kalsekar I., et al. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2011, 17:916-922.
55. Schleuning M., Judith D., Jedlickova Z., et al. Calcineurin inhibitor-free GVHD prophylaxis with sirolimus, mycophenolate mofetil and ATG in Allo-SCT for leukemia patients with high relapse risk: an observational cohort study. Bone Marrow Transplant 2009, 43:717-723.
56. BMT CTN #0402. A phase III randomized, multicenter trial comparing sirolimus/tacrolimus with tacrolimus/methotrexate as graft-versus-host disease (GVHD) prophylaxis after HLA-matched, related peripheral blood stem cell transplantation (BMT CTN #0402). Available at: http://clinicaltrials.gov/ct2/show/NCT00406393.
57. Schmid C., Schleuning M., Ledderose G., Tischer J., Kolb H.J. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005, 23:5675-5687.
58. Schmid C., Schleuning M., Schwerdtfeger R., et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006, 108:1092-1099.
59. Pidala J., Tomblyn M., Nishihori T., et al. Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids. Haematologica 2011, 96:1351-1356.
60. Ghez D., Rubio M.T., Maillard N., et al. Rapamycin for refractory acute graft-versus-host disease. Transplantation 2009, 88:1081-1087.
61. Hoda D., Pidala J., Salgado-Vila N., et al. Sirolimus for treatment of steroid-refractory acute graft-versus-host disease. Bone Marrow Transplant 2010, 45:1347-1351.
62. Jurado M., Vallejo C., Pérez-Simón J.A., et al. Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007, 13:701-706.
63. Couriel D.R., Saliba R., Escalón M.P., et al. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol 2005, 130:409-417.
64. Goldberg J. A Phase II/III Randomized, Multicenter Trial Comparing Sirolimus Plus Prednisone, Sirolimus/Extracorporeal Photopheresis Plus Prednisone, and Sirolimus/Calcineurin Inhibitor Plus Prednisone for the Treatment of Chronic Graft-versus-Host Disease. Available at: http://www.mskcc.org/cancer-care/trial/10-201.
65. Armand P., Gannamaneni S., Kim H.T., et al. Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol 2008, 26:5767-5774.
66. Furlong T., Kiem H.P., Appelbaum F.R., et al. Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors. Biol Blood Marrow Transplant 2008, 14:531-537.
67. Benito A.I., Furlong T., Martin P.J., et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 2001, 72:1924-1929.
68. Zeiser R., Nguyen V.H., Beilhack A., et al. Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 2006, 108:390-399.